Himalaya Wellness, CSIR-CDRI join forces to develop new therapy for Polyendocrine Metabolic Ovarian Syndrome

Himalaya Wellness Company has entered into a licensing agreement with the Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, to develop a new evidence-based intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as Polycystic Ovary Syndrome (PCOS).

The collaboration brings together CSIR-CDRI’s expertise in drug discovery and phytopharmaceutical research with Himalaya’s capabilities in herbal research and product development. The partnership aims to advance the discovery and development of a safe and effective therapy for PMOS, a complex condition that affects approximately 1 in 8 women and more than 170 million people globally.

Unlike conditions that affect a single organ or pathway, PMOS involves interconnected reproductive, metabolic, and endocrine factors. This complexity can make its management challenging and underscores the need for approaches that address the condition more comprehensively.

Under the agreement, a standardised herbal extract developed by CSIR-CDRI scientists, Dr T. Narender and Dr Rajesh Jha, will be advanced by Himalaya Wellness Company, for its potential application in PMOS. The company will focus on formulation development, clinical safety, and efficacy evaluation, with the broader objective of translating scientific research into a potential therapeutic option for women.

The collaboration reflects the growing importance of industry-academia partnerships in translating scientific discoveries into potential healthcare applications. By combining research capabilities, such partnerships can help advance innovation while enabling specialised scientific expertise and industry development capabilities to work towards a common healthcare objective.